|
| 36797947 | Nonequilibrium statistical physics beyond the ideal heat bath approximation. | Phys Rev E | 2023 |
| 37858338 | High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma. | Cell Rep Med | 2023 |
| 37053187 | Early path dominance as a principle for neurodevelopment. | Proc Natl Acad Sci U S A | 2023 |
| 37140091 | In vivo activity of the dual PI3Kδ and PI3Kγ inhibitor duvelisib against pediatric acute lymphoblastic leukemia xenografts. | Pediatr Blood Cancer | 2023 |
| 37071496 | Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model. | Clin Cancer Res | 2023 |
| 36882482 | Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib. | Sci Rep | 2023 |
| 35084470 | PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity. | Blood | 2022 |
| 35467979 | Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155/TIGIT axis. | Proc Natl Acad Sci U S A | 2022 |
| 35718227 | Dual Stromal Targeting Sensitizes Pancreatic Adenocarcinoma for Anti-Programmed Cell Death Protein 1 Therapy. | Gastroenterology | 2022 |
| 36075300 | Review of the application of Kirchhoff's Laws of series and parallel flows to pharmacology: Defining organ clearance. | Pharmacol Ther | 2022 |
| 34050172 | FAK inhibition alone or in combination with adjuvant therapies reduces cancer stem cell activity. | NPJ Breast Cancer | 2021 |
| 33568347 | Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for <i>GNAQ</i>-Driven Uveal Melanoma. | Clin Cancer Res | 2021 |
| 33786583 | Synergistic efficacy of the dual PI3K-δ/γ inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models. | Blood | 2021 |
| 34389658 | Correction: Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for <i>GNAQ</i>-Driven Uveal Melanoma. | Clin Cancer Res | 2021 |
| 31076405 | Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion. | Gut | 2020 |
| 32793908 | Natural Killer cell activation, reduced ACE2, TMPRSS2, cytokines G-CSF, M-CSF and SARS-CoV-2-S pseudovirus infectivity by MEK inhibitor treatment of human cells. | bioRxiv | 2020 |
| 32404407 | Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia. | Mol Cancer Ther | 2020 |
| 30342021 | Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors. | Biochem Pharmacol | 2019 |
| 31478830 | FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy. | Elife | 2019 |
| 30785827 | Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study. | J Clin Oncol | 2019 |
| 30655367 | PYK2/FAK inhibitors reverse hypoxia-induced drug resistance in multiple myeloma. | Haematologica | 2019 |
| 28692661 | The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma. | PLoS One | 2017 |
| 28270436 | Focal Adhesion Kinase as a Potential Target in AML and MDS. | Mol Cancer Ther | 2017 |
| 29050315 | The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated <i>EGFR</i> gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells. | Oncotarget | 2017 |
| 28881682 | Inhibition of FAK kinase activity preferentially targets cancer stem cells. | Oncotarget | 2017 |
| 27376576 | Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. | Nat Med | 2016 |
| 26387544 | Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma. | Oncogene | 2016 |
| 27123491 | Synergism of FAK and tyrosine kinase inhibition in Ph<sup>+</sup> B-ALL. | JCI Insight | 2016 |
| 25432176 | PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells. | Cancer Res | 2015 |
| 26406376 | Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity. | Cell | 2015 |
| 24371224 | Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis. | Cancer Res | 2014 |
| 25217697 | Pyk2 promotes tumor progression in multiple myeloma. | Blood | 2014 |
| 24848258 | Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship. | Sci Transl Med | 2014 |
| 23317569 | Discovery of potent, selective and orally bioavailable imidazo[1,5-a]pyrazine derived ACK1 inhibitors. | Bioorg Med Chem Lett | 2013 |
| 24900721 | Discovery of novel insulin-like growth factor-1 receptor inhibitors with unique time-dependent binding kinetics. | ACS Med Chem Lett | 2013 |
| 23773865 | Novel 6-aminofuro[3,2-c]pyridines as potent, orally efficacious inhibitors of cMET and RON kinases. | Bioorg Med Chem Lett | 2013 |
| 22942252 | ROCK1 and ROCK2 are required for non-small cell lung cancer anchorage-independent growth and invasion. | Cancer Res | 2012 |
| 21251824 | Potent and selective cyclohexyl-derived imidazopyrazine insulin-like growth factor 1 receptor inhibitors with in vivo efficacy. | Bioorg Med Chem Lett | 2011 |
| 21643654 | Inducible expression of TGFβ, snail and Zeb1 recapitulates EMT in vitro and in vivo in a NSCLC model. | Clin Exp Metastasis | 2011 |
| 21673091 | Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin. | Mol Cancer Ther | 2011 |
| 21353551 | Imidazo[1,5-a]pyrazines: orally efficacious inhibitors of mTORC1 and mTORC2. | Bioorg Med Chem Lett | 2011 |
| 21041998 | Cooperative signaling between oncostatin M, hepatocyte growth factor and transforming growth factor-β enhances epithelial to mesenchymal transition in lung and pancreatic tumor models. | Cells Tissues Organs | 2011 |
| 20124453 | A fully human insulin-like growth factor-I receptor antibody SCH 717454 (Robatumumab) has antitumor activity as a single agent and in combination with cytotoxics in pediatric tumor xenografts. | Mol Cancer Ther | 2010 |
| 24900240 | Discovery of an Orally Efficacious Imidazo[5,1-f][1,2,4]triazine Dual Inhibitor of IGF-1R and IR. | ACS Med Chem Lett | 2010 |
| 20924128 | Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer. | Mol Cancer Ther | 2010 |
| 19895344 | High-throughput screening for mTORC1/mTORC2 kinase inhibitors using a chemiluminescence-based ELISA assay. | Assay Drug Dev Technol | 2009 |
| 18374184 | Quantitative high-throughput cell-based assays for inhibitors of ROCK kinases. | Methods Enzymol | 2008 |
| 18922904 | Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. | Cancer Res | 2008 |
| 17671083 | A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo. | Mol Cancer Ther | 2007 |
| 17607936 | Inhibition of the IGF-I receptor for treatment of cancer. Kinase inhibitors and monoclonal antibodies as alternative approaches. | Recent Results Cancer Res | 2007 |